3D bioprinting employs 3D printing techniques to create bioclinical parts by combining cells, growth factors, and biomaterials, aiming to mimic natural tissue characteristics. It typically involves layer-by-layer deposition of bioinks to produce tissue-like structures, which find applications in various clinical and tissue-related fields.
The global population of people aged 60 and above is increasing at a faster rate compared to younger age groups. This demographic shift is expected to have a significant impact on the growth of the global 3D bioprinting market. By 2025, the number of individuals over 60 is projected to double. This trend highlights the growing demand for caregivers who can provide round-the-clock care, not just in healthcare facilities and nursing homes but also in apartments and private residences.
In 2021, the 3D Bioprinting Market had a valuation of US$ 875.33 million, and it is projected to achieve a value of US$ 4,815.02 million by 2030, with a compound annual growth rate (CAGR) of 21% from 2022 to 2030.
In terms of volume, North America was the leading player in the global 3D bioprinting market in 2021, capturing a significant 40% share.
Leading Companies in the 3D Bioprinting Industry:
- 3D Systems Corporation
3D Systems Corporation was established in 1986 and is headquartered in Rock Hill, South Carolina, United States. It operates in more than 68 countries and is engaged in various industries, including 3D printing, 3D technology, industrial engineering, mechanical engineering, software, and technical support. In 2021, the 3D systems will adopt additive manufacturing to increase the AM software assortment and the creation capacity, which will increase with additive production in the industrial and hospital markets.
- EnvisionTEC GmbH
EnvisionTEC GmbH was established in 2002 and is headquartered in Dearborn, Mich. It is engaged in various industries, including 3D printing, industrials, and manufacturing. In 2021, EnvisionTEC and Covestro announced their collaboration on material and printer solutions to accelerate the adoption of industrial 3D printing.
- Stratasys Ltd
Stratasys Ltd. was established in 1989 and is headquartered in Rehovot, Israel. It operates in 13 countries and is engaged in manufacturing machines that help with prototyping and producing plastic parts. In 2023, Stratasys Ltd. announced it had completed the acquisition of the additive manufacturing materials business of Covestro AG.
- Aspect Biosystems Ltd.
Aspect Biosystems Ltd. was established in 2013 and is headquartered in Vancouver, British Columbia. It is engaged in developing bioprinted tissue therapeutics. In 2019, Aspect Biosystems announced its involvement in a $2.2 million project seeking to find new treatments for cancer.
- ARCAM AB (a GE Company)
ARCAM AB (a GE Company) was established in 1997 and is headquartered in Mölndal, Sweden. It is engaged in various industries, including 3D bioprinting, software, and hardware, and manufacturing.
- Cellink AB
Cellink AB was established in 2016 and is headquartered in Gothenburg, Sweden. It operates in more than 65 countries and is engaged in various industries, including 3D printing, biotechnology, life science, and medical.
- REGEMAT 3D
REGEMAT 3D was established in 2015 and is headquartered in Armilla, Andalucia, Spain. It operates in more than 25 countries and is engaged in various industries, including 3D printing, biotechnology, and manufacturing.
- Organovo Holdings Inc.
Organovo Holdings Inc. was established in 2007 and is headquartered in San Diego, California. It is engaged in various industries, including biotechnology, medical, and therapeutics.
Definition: 3D bioprinting is a technique that uses specialized printers to create three-dimensional structures by layering living cells.
